Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai’s Leqembi Added to China Commercial Insurance Drug List
Eisai said on December 9 that its early Alzheimer’s disease therapy Leqembi (lecanemab) has been included in a newly created “Commercial Insurance Innovative Drug List” compiled by China’s National Healthcare Security Administration. The list is part of a new policy…
To read the full story
Related Article
- China Approves Monthly IV Maintenance Dosing of Leqembi
September 30, 2025
- Eisai’s Alzheimer’s Med Leqembi Now Available in China
July 1, 2024
BUSINESS
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Rakuten to Launch Japan PI of RM-0256 Photoimmunotherapy in April-June
February 17, 2026
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
- Ono’s Velexbru Accepted for FDA Review in PCNSL
February 17, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…